Nat Turner is the co-founder and CEO of Flatiron Health, a healthcare technology company that focuses on improving cancer care through data-driven solutions. Though he shares a name with the famous 19th-century American slave and rebellion leader, Nat Turner the entrepreneur has made his own significant mark in the modern healthcare landscape by leveraging technology to transform oncology treatment and research. Under his leadership, Flatiron Health has grown into a prominent player in the digital health arena, helping to accelerate cancer research with real-world evidence and providing oncologists with advanced tools. This article highlights ten key facts about Nat Turner’s career, Flatiron Health’s impact, and the evolving role of healthcare technology in cancer treatment.
Nat Turner studied at the University of Pennsylvania, where he earned a degree in economics. Before founding Flatiron Health, he gained valuable experience in finance and entrepreneurship. His academic background and early exposure to the world of startups helped him develop a strong foundation in business and innovation. Turner's passion for improving healthcare through technology led him to co-found Flatiron Health in 2012 alongside his brother, Zach Turner, and oncologist Dr. Natanael (Nat) Stein.
Flatiron Health was founded with the goal of harnessing real-world clinical data to optimize cancer care and accelerate research. Recognizing the challenges faced by oncologists in accessing and analyzing patient data scattered across various systems, Turner and his team created a platform that enables aggregation and analysis of this information. The company's intuitive software solutions help clinicians make more informed treatment decisions and support pharmaceutical research efforts.
One of Flatiron Health’s core innovations is the use of real-world evidence (RWE), which refers to clinical data collected outside traditional clinical trials. This data comes from electronic health records, insurance claims, and patient registries. Turner's leadership helped position Flatiron as a pioneer in integrating RWE into oncology research and drug development, providing more comprehensive insights into how treatments perform in everyday clinical settings.
In 2018, Flatiron Health was acquired by Roche, a global leader in pharmaceuticals and diagnostics, for an estimated $1.9 billion. This acquisition was one of the largest private deals in the health technology space at the time and underscored the strategic importance of real-world data in developing new therapies. Turner remained CEO post-acquisition, leveraging Roche’s resources to scale Flatiron’s impact.
Under Nat Turner’s guidance, Flatiron Health has significantly influenced the delivery of cancer care. The company’s software allows oncologists to access comprehensive patient histories, track treatment outcomes, and manage clinical workflows more effectively. By enabling personalized treatment planning and facilitating clinical trial matching, Flatiron has helped improve patient outcomes and streamline care processes.
The platform developed by Flatiron Health has become a vital tool for researchers and pharmaceutical companies. By making large volumes of de-identified patient data accessible, Flatiron enables more rapid and cost-effective clinical studies. This is especially important in oncology, where drug development can be lengthy and expensive. Turner's vision has helped shorten the timeline for bringing new cancer therapies to market.
Despite its successes, Turner has acknowledged the challenges of integrating complex healthcare data across multiple systems. Privacy concerns, data standardization, and interoperability are ongoing issues in the industry. Flatiron Health continues to address these challenges by developing secure data frameworks and collaborating with healthcare providers to ensure data quality and compliance.
Flatiron Health places a strong emphasis on maintaining patient privacy and ethical standards in data use. Under Turner's leadership, the company enforces stringent protocols that comply with healthcare regulations such as HIPAA. Ensuring patient anonymity while delivering usable datasets has been critical to building trust among patients, providers, and partners.
Nat Turner’s leadership is characterized by a mission-driven approach centered on improving patient outcomes. He fosters a culture of innovation, collaboration, and transparency at Flatiron Health. His commitment to leveraging technology for social good has propelled the company’s growth and positioned it at the forefront of healthcare digital transformation.
Looking ahead, Nat Turner envisions Flatiron Health expanding its offerings through artificial intelligence and machine learning to further enhance oncology care. The company is exploring predictive analytics to improve early detection and personalized treatment plans. Turner's ongoing focus is on broadening the application of real-world data in other therapeutic areas, signaling a future where data-driven care becomes a standard across all medical fields.
Nat Turner’s journey from economics graduate to pioneering healthcare CEO illustrates the transformative power of technology in medicine. Through Flatiron Health, he has revolutionized the way cancer care and research are conducted by utilizing real-world data to improve outcomes and accelerate innovation. As the company continues to evolve, its impact on oncology and broader healthcare sectors is likely to grow, demonstrating the vital role entrepreneurs like Turner play in shaping the future of health. His story invites us to reflect on how data and technology can be harnessed responsibly to tackle some of the most pressing medical challenges of our time.
